|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Digital Content 3. Characteristics of Spencer Cox Center (SCC) patients who died** | | | | | | |
|  |  | | **By SCC Retention status** | | | |
|  | **SCC Patients died  2010 - 2012** | | **Retained: additional ≥1 SCC visit in 2012** | | **Not retained: No SCC visits in 2012** | |
|  | **N** | **%** | **N** | **%** | **N** | **%** |
| **Total** | **252** | **100.0** | **55** | **100.0** | **197** | **100.0** |
| **Sex** |  |  |  |  |  |  |
| Male | 183 | 72.6 | 45 | 81.8 | 138 | 70.1 |
| Female | 69 | 27.4 | 10 | 18.2 | 59 | 29.9 |
| **Race/Ethnicity** |  |  |  |  |  |  |
| Black | 119 | 47.2 | 24 | 43.6 | 95 | 48.2 |
| Hispanic | 97 | 38.5 | 22 | 40.0 | 75 | 38.1 |
| White | 36 | 14.3 | 9 | 16.4 | 27 | 13.7 |
| Asian/Pacific Islander | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other/Unknown1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| **Age group (years) at death** |  |  |  |  |  |  |
| 18-29 | 5 | 2.0 | 0 | 0.0 | 5 | 2.5 |
| 30-39 | 19 | 7.5 | 3 | 5.5 | 16 | 8.1 |
| 40-49 | 65 | 25.8 | 11 | 20.0 | 54 | 27.4 |
| 50-59 | 103 | 40.9 | 25 | 45.5 | 78 | 39.6 |
| 60+ | 60 | 23.8 | 16 | 29.1 | 44 | 22.3 |
| **Year of HIV diagnosis** |  |  |  |  |  |  |
| ≤ 1996 | 129 | 51.2 | 27 | 49.1 | 102 | 51.8 |
| 1997-2000 | 61 | 24.2 | 15 | 27.3 | 46 | 23.4 |
| 2001-2005 | 33 | 13.1 | 7 | 12.7 | 26 | 13.2 |
| 2006-2010 | 27 | 10.7 | 5 | 9.1 | 22 | 11.2 |
| 2011-2012 | 2 | 0.8 | 1 | 1.8 | 1 | 0.5 |
| **Area-based poverty level - residence at last SCC visit2** |  |  |  |  |  |  |
| Low poverty (<10% below FPL) | 25 | 9.9 | 8 | 14.5 | 17 | 8.6 |
| Medium poverty (10 to <20% below FPL) | 82 | 32.5 | 14 | 25.5 | 68 | 34.5 |
| High poverty (20 to <30% below FPL) | 65 | 25.8 | 16 | 29.1 | 49 | 24.9 |
| Very high poverty (≥30% below FPL) | 79 | 31.3 | 17 | 30.9 | 62 | 31.5 |
| Area-based poverty level not available | 1 | 0.4 | 0 | 0.0 | 1 | 0.5 |
| **Transmission risk** |  |  |  |  |  |  |
| Men who have sex with men | 58 | 23.0 | 17 | 30.9 | 41 | 20.8 |
| Injection drug use history | 104 | 41.3 | 22 | 40.0 | 82 | 41.6 |
| Heterosexual3 | 37 | 14.7 | 5 | 9.1 | 32 | 16.2 |
| Perinatal | 2 | 0.8 | 0 | 0.0 | 2 | 1.0 |
| Other | 0 | 0.0 |  |  | 0 | 0.0 |
| Unknown | 51 | 20.2 | 11 | 20.0 | 40 | 20.3 |
|  |  |  |  |  |  |  |
| **Median time from last SCC visit to death,**  **days (range)** | 62 (1 - 966) | | 32 (2 - 195) | | 79 (1 - 966) | |
|  |  |  |  |  |  |  |
| **Time from SCC visit to death** |  |  |  |  |  |  |
| 0 - 1 month | 77 | 30.6 | 26 | 47.3 | 51 | 25.9 |
| >1 month - 3 months | 75 | 29.8 | 20 | 36.4 | 55 | 27.9 |
| >3 - 6 months | 33 | 13.1 | 8 | 14.5 | 25 | 12.7 |
| >6 months | 67 | 26.6 | 1 | 1.8 | 66 | 33.5 |
| **Virally suppressed (≤200 copies/mL)**  **at most recent SCC visit4** |  |  |  |  |  |  |
| Yes | 114 | 45.2 | 38 | 69.1 | 76 | 38.6 |
| No | 135 | 53.6 | 17 | 30.9 | 118 | 59.9 |
| Unknown - no VL prior to SCC visit | 3 | 1.2 | 0 | 0.0 | 3 | 1.5 |
|  |  |  |  |  |  |  |
| **Median viral load (copies/mL) among unsuppressed**  **at most recent SCC visit (IQR)4** | 31,881 (4,887 - 100,000) | | 68,165 (4,592 - 228,628) | | 29,650.5 4,970 - 100,000) | |
|  |  |  |  |  |  |  |
| **CD4 (cells/μL) at most recent SCC visit4** |  |  |  |  |  |  |
| ≤ 200 | 116 | 46.0 | 18 | 32.7 | 98 | 49.7 |
| 201 - 349 | 57 | 22.6 | 17 | 30.9 | 40 | 20.3 |
| 350 - 500 | 38 | 15.1 | 7 | 12.7 | 31 | 15.7 |
| ≥ 501 | 40 | 15.9 | 13 | 23.6 | 27 | 13.7 |
| Unknown - no CD4 in 2012 | 1 | 0.4 | 0 | 0.0 | 1 | 0.5 |
|  |  |  |  |  |  |  |
| **Median CD4 cell count (cells/μL)**  **most recent SCC visit (IQR)4** | 209 (81 - 413) | | 261 (121 - 420) | | 197.5 (68.5 - 402.5) | |
|  |  |  |  |  |  |  |
| **SCC clinic care status as of December 31, 2012** |  |  |  |  |  |  |
| Retained in care: ≥1 SC clinic visit January 1 - December 31, 2012 | 55 | 21.8 | 55 | 100.0 | 0 | 0.0 |
| Lost to clinic: no SC clinic visits January 1 - December 31, 2012 | 197 | 78.2 | 0 | 0.0 | 197 | 100.0 |
| **Among lost to clinic: in care at alternate facility after most recent SCC clinic visit5** |  |  |  |  |  |  |
| Yes | n/a | n/a | n/a | n/a | 32 | 16.2 |
| No - ≥1 lab but did not meet in care definition | n/a | n/a | n/a | n/a | 96 | 48.7 |
| No - 0 labs reported after most recent SC clinic visit | n/a | n/a | n/a | n/a | 69 | 35.0 |
|  |  |  |  |  |  |  |
| **Cause of death** |  |  |  |  |  |  |
| HIV-related | 103 | 40.9 | 16 | 29.1 | 87 | 44.2 |
| Non-HIV-related | 149 | 59.1 | 39 | 70.9 | 110 | 55.8 |
| *Malignant neoplasms* | *35* | *13.9* | *12* | *21.8* | *23* | *11.7* |
| *Major cardiovascular diseases* | *39* | *15.5* | *10* | *18.2* | *29* | *14.7* |
| *Accidents* | *18* | *7.1* | *3* | *5.5* | *15* | *7.6* |
| *All other natural causes-rest of A00-R99* | *10* | *4.0* | *2* | *3.6* | *8* | *4.1* |
| *Mental and behavioral disorders*  *(use of psychoactive excl. tobacco and alcohol)* | *8* | *3.2* | *3* | *5.5* | *5* | *2.5* |
| *Influenza and pneumonia* | *7* | *2.8* | *0* | *0.0* | *7* | *3.6* |
| *Unknown* | *6* | *2.4* | *2* | *3.6* | *4* | *2.0* |
| *Chronic liver disease and cirrhosis* | *5* | *2.0* | *1* | *1.8* | *4* | *2.0* |
| *Intentional self-harm (suicide)* | *5* | *2.0* | *3* | *5.5* | *2* | *1.0* |
| *Viral hepatitis* | *4* | *1.6* | *0* | *0.0* | *4* | *2.0* |
| *Assault (homicide)* | *4* | *1.6* | *1* | *1.8* | *3* | *1.5* |
| *Chronic lower respiratory diseases* | *3* | *1.2* | *1* | *1.8* | *2* | *1.0* |
| *Septicemia* | *1* | *0.4* | *1* | *1.8* | *0* | *0.0* |
| *All other infective and parasitic diseases* | *1* | *0.4* | *0* | *0.0* | *1* | *0.5* |
| *In situ or benign neoplasms and neoplasms*  *of uncertain or unknown behavior* | *1* | *0.4* | *0* | *0.0* | *1* | *0.5* |
| *Diabetes mellitus* | *1* | *0.4* | *0* | *0.0* | *1* | *0.5* |
| *Events of undetermined intent* | *1* | *0.4* | *0* | *0.0* | *1* | *0.5* |
| FPL= Federal poverty level | | |  |  |  |  |
| Prepared September 2014 by the DOHMH BHIV Prevention and Control with data reported as of March 31, 2014 | | | | | | |
| 1Includes Native American and Multiracial. | | | | | | |
| 2Poverty level based on most recent NYC ZIP code of residence at most recent SCC visit 2010-2012. Not available for persons missing ZIP code information or living outside NYC. | | | | | | |
| 3Includes persons who had heterosexual sex with a person they know to be HIV-infected, an injection drug user, or a person who has received blood products. For females only, also includes history of prostitution, multiple sex partners, sexually transmitted disease, crack/cocaine use, sex with a bisexual male, probable heterosexual transmission as noted in medical chart, or sex with a male and negative history of injection drug use. | | | | | | |
| 4Viral suppression, median viral load, CD4 category and median CD4 count are determined by a patient's most recent CD4/VL test on or before their most recent SCC visit 2010 - 2012. | | | | | | |
| 5In care was defined as ≥2 CD4VL tests ≥90 days apart ordered by the same provider any time after a patient's most recent SCC visit date and reported to the NYC HIV Surveillance Registry. | | | | | | |